Thursday, March 31, 2011
Researchers from Cyprus have developed a
rapid, noninvasive diagnostic for Down syndrome that detects methylated fetal
DNA in the blood of pregnant women.1 The team's leader has founded a
new company-NIPD Genetics Ltd.-to
commercialize the technique, which will compete with DNA sequencing-based
methods from Sequenom Inc. and Artemis Health Inc.
Down for the count
Osherovich, L. SciBX 4(13);
doi:10.1038/scibx.2011.360 Published online March 31, 2011
1. Papageorgiou, E.A. et al. Nat. Med.;
published online March 6, 2011; doi:10.1038/nm.2312 Contact: Philippos C.
Patsalis, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus e-mail:
2. Chiu, R.W.K. et al. Proc. Natl. Acad. Sci.
105, 20458-20463 (2008)
3. Osherovich, L. SciBX 3(25); doi:10.1038/scibx.2010.752
4. Usdin, S. BioCentury 18(52), A1-A5; Dec. 6, 2010
COMPANIES AND INSTITUTIONS MENTIONED
American College of Medical Genetics,
Artemis Health Inc., Menlo
Chinese University of Hong Kong, Hong Kong, China
Institute of Neurology and Genetics, Nicosia, Cyprus
NIPD Genetics Ltd., Nicosia,
Sequenom Inc. (NASDAQ:SQNM),
San Diego, Calif.
University, Stanford, Calif.